Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
作者信息
Duncavage Eric J, Uy Geoffrey L, Petti Allegra A, Miller Christopher A, Lee Yi-Shan, Tandon Bevan, Gao Feng, Fronick Catrina C, O'Laughlin Michelle, Fulton Robert S, Wilson Richard K, Jacoby Meagan A, Cashen Amanda F, Wartman Lukas D, Walter Matthew J, Westervelt Peter, Link Daniel C, DiPersio John F, Ley Timothy J, Welch John S
机构信息
Department of Pathology and Immunology.
Division of Oncology, Department of Internal Medicine.
出版信息
Blood. 2017 Mar 9;129(10):1397-1401. doi: 10.1182/blood-2016-10-745273. Epub 2017 Jan 12.
Abstract
摘要
相似文献
1
Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.在地西他滨治疗期间，急性髓系白血病（AML）和骨髓增生异常综合征（MDS）患者外周血中的突变图谱和反应是保守的。
Blood. 2017 Mar 9;129(10):1397-1401. doi: 10.1182/blood-2016-10-745273. Epub 2017 Jan 12.
2
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.TP53与地西他滨在急性髓系白血病和骨髓增生异常综合征中的应用
N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.
3
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.地西他滨分别联合复杂核型治疗急性髓系白血病和骨髓增生异常综合征。
Asian Pac J Cancer Prev. 2015;16(15):6627-32. doi: 10.7314/apjcp.2015.16.15.6627.
4
Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.阿扎胞苷治疗失败后，骨髓增生异常综合征和急性髓系白血病对地西他滨缺乏客观反应。
Leuk Lymphoma. 2015 Jun;56(6):1718-22. doi: 10.3109/10428194.2014.966708. Epub 2014 Nov 3.
5
Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.与传统化疗相比，在高危骨髓肿瘤中，先用地西他滨进行表观遗传启动，再给予低剂量伊达比星/阿糖胞苷，具有增强的抗白血病作用。
Leuk Lymphoma. 2016;57(6):1311-8. doi: 10.3109/10428194.2015.1091931. Epub 2015 Oct 13.
6
The euphoria of hypomethylating agents in MDS and AML: is it justified?低甲基化药物在 MDS 和 AML 中的兴奋：这合理吗？
Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15.
7
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.TET2 突变对低细胞性骨髓增生异常综合征和低原始细胞性急性髓系白血病患者阿扎胞苷治疗反应率的影响。
Leukemia. 2011 Jul;25(7):1147-52. doi: 10.1038/leu.2011.71. Epub 2011 Apr 15.
8
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.地西他滨诱导的表观遗传学重编程序贯低剂量伊达比星和阿糖胞苷治疗由骨髓增生异常综合征和高危骨髓增生异常综合征进展而来的急性髓系白血病：一项前瞻性多中心单臂试验。
Hematol Oncol. 2020 Oct;38(4):531-540. doi: 10.1002/hon.2755. Epub 2020 Jun 24.
9
[The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].低剂量皮下注射地西他滨治疗老年急性髓系白血病及中高危骨髓增生异常综合征的临床安全性与疗效
Zhonghua Nei Ke Za Zhi. 2017 Aug 1;56(8):606-609. doi: 10.3760/cma.j.issn.0578-1426.2017.08.010.
10
[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].5天阿扎胞苷治疗伴有复杂核型异常的骨髓增生异常综合征及急性髓系白血病
Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019.
引用本文的文献
1
Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study.来自国家骨髓增生异常综合征（MDS）研究的MDS患者外周血与骨髓突变之间的相关性
Blood Neoplasia. 2024 Jun 12;1(3):100026. doi: 10.1016/j.bneo.2024.100026. eCollection 2024 Sep.
2
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.突破骨髓屏障：外周血作为急性髓系白血病可测量残留病检测的途径
Am J Hematol. 2025 Apr;100(4):638-651. doi: 10.1002/ajh.27586. Epub 2025 Jan 7.
3
Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.监测克隆负荷作为骨髓增生异常综合征治疗反应中原始细胞计数的替代指标。
Leukemia. 2025 Jan;39(1):166-177. doi: 10.1038/s41375-024-02426-0. Epub 2024 Oct 4.
4
Molecular responses in decitabine- and decitabine/ venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes.地西他滨和地西他滨/维奈克拉治疗的急性髓系白血病和骨髓增生异常综合征患者的分子反应
Haematologica. 2024 Aug 1;109(8):2653-2659. doi: 10.3324/haematol.2022.281396.
5
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax.DNA 高甲基化导致 miR-182 表达降低，通过靶向 PBX3 和 BCL2 加速急性淋巴细胞白血病的发展：miR-182 启动子甲基化是低甲基化剂+BCL2 抑制剂 venetoclax 的预测标志物。
Clin Epigenetics. 2024 Mar 26;16(1):48. doi: 10.1186/s13148-024-01658-2.
6
How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome.如何基于临床和分子建模进行风险分类：将分子标志物整合到骨髓增生异常综合征的风险评估中。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):51-58. doi: 10.1182/hematology.2023000420.
7
Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes.迈向骨髓增生异常综合征中可测量残留疾病的概念化。
Blood Adv. 2023 Aug 22;7(16):4381-4394. doi: 10.1182/bloodadvances.2023010098.
8
Clonal dynamics using droplet digital polymerase chain reaction in peripheral blood predicts treatment responses in myelodysplastic syndrome.利用外周血中的微滴式数字聚合酶链反应进行克隆动态分析可预测骨髓增生异常综合征的治疗反应。
Haematologica. 2023 Jul 1;108(7):1951-1956. doi: 10.3324/haematol.2022.281595.
9
Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution.范可尼贫血向骨髓增生异常综合征和急性髓系白血病的多克隆演化在单细胞分辨率下得以揭示。
Exp Hematol Oncol. 2022 Sep 27;11(1):64. doi: 10.1186/s40164-022-00319-5.
10
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.基因组分析在髓系肿瘤和急性白血病中的临床决策应用。
Blood. 2022 Nov 24;140(21):2228-2247. doi: 10.1182/blood.2022015853.
本文引用的文献
1
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.TP53与地西他滨在急性髓系白血病和骨髓增生异常综合征中的应用
N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.
2
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents.在对去甲基化药物有反应的慢性粒单核细胞白血病中，突变等位基因负担保持不变。
Nat Commun. 2016 Feb 24;7:10767. doi: 10.1038/ncomms10767.
3
Assessment of Minimal Residual Disease in Standard-Risk AML.标准风险 AML 中的微小残留病评估。
N Engl J Med. 2016 Feb 4;374(5):422-33. doi: 10.1056/NEJMoa1507471. Epub 2016 Jan 20.
4
Optimizing cancer genome sequencing and analysis.优化癌症基因组测序与分析。
Cell Syst. 2015 Sep 23;1(3):210-223. doi: 10.1016/j.cels.2015.08.015.
5
Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.对于初发急性髓系白血病（AML）患者，诱导治疗后常出现原有非白血病造血克隆的快速扩增。
Blood. 2016 Feb 18;127(7):893-7. doi: 10.1182/blood-2015-10-677021. Epub 2015 Dec 2.
6
MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.MDS相关的体细胞突变和克隆性造血在意义未明的特发性血细胞减少症中很常见。
Blood. 2015 Nov 19;126(21):2355-61. doi: 10.1182/blood-2015-08-667063. Epub 2015 Oct 1.
7
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.诱导治疗后突变清除与急性髓系白血病预后的关联
JAMA. 2015 Aug 25;314(8):811-22. doi: 10.1001/jama.2015.9643.
8
Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy.急性髓系白血病患者诱导治疗第14天时骨髓穿刺物的评估。
Diagn Pathol. 2015 Jul 25;10:122. doi: 10.1186/s13000-015-0365-2.
9
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).骨髓增生异常综合征（MDS）患者外周血和骨髓中的基因组和细胞遗传学异常具有高度一致性。
Leukemia. 2015 Sep;29(9):1928-38. doi: 10.1038/leu.2015.110. Epub 2015 May 6.
10
Correlation between peripheral blood and bone marrow regarding FLT3-ITD and NPM1 mutational status in patients with acute myeloid leukemia.急性髓系白血病患者外周血与骨髓中FLT3-ITD和NPM1突变状态的相关性
Haematologica. 2015 Mar;100(3):e97-8. doi: 10.3324/haematol.2014.118422. Epub 2014 Dec 19.
Zotero 插件